May 4, 2013 -- Shanghai Fosun Pharma, Chindex and a private equity partner will spend $240 million to buy a 95.6% stake in Alma Lasers, an Israeli medical device company; Ascletis, a China-US drug developer, in-licensed China rights to a next-generation HIV protease inhibitor from Janssen R&D Ireland; Zhejiang Huahai Pharma raised $126 million in a ... (more)
http://www.biospace.com/news_story.aspx?StoryID=295424&full=1
http://www.biospace.com/news_story.aspx?StoryID=295424&full=1
No comments:
Post a Comment